Varenicline (Chantix), a common anti-smoking drug may increase cardiovascular disease risk
Varenicline (brand name Chantix) is an anti-smoking drug which helps smokers to quit the smoking habit. Earlier studies on the safety of varenicline were conflicting and they were conducted under highly controlled settings among individuals with similar features and backgrounds. An earlier study conducted under highly controlled settings shows usage of varenicline drug causes triple-risk to cardiovascular events.
The risk of cardiovascular events increases when cells of the heart muscle do not receive sufficient oxygen and energy-rich blood. This event is caused due to narrowing of arteries (atherosclerosis disease) connected to the heart. The important cardiovascular events associated with insufficient blood supply to heart are
A current observational, population-based and self-controlled analytical study shows an increased risk to the development of cardiovascular events with the use of varenicline (brand name Chantix), an anti-smoking drug.
The current study has been conducted among different people. They analyzed health records of 56,851 individuals taking varenicline drug between 2011 and 2015 in Ontario, Canada. They focused more in one year before and one year after the health of those individuals who took varenicline drug for 3 months (12 weeks).
The analytical study results show following observations.
Researchers say that their study is not suggesting not to use varenicline drug to quit smoking. An individual should consider potential cardiovascular health risks and probable heart health benefits with varenicline drug usage. Researchers also say health care professionals should monitor the health of varenicline drug patient for the early detection of potential heart problems.
But this study is not showing cause and effect relationship and this study was not intended to find the mechanism behind the development of cardiovascular events with the use of varenicline anti-smoking drug.
Lead author of the study was Dr. Andrea S. Gershon, MD, a Fellow of the Royal College of Physicians of Canada (FRCPC) and an associate professor of medicine, University of Toronto, Canada. The study findings were published December 20, 2017, in the American Journal of Respiratory and Critical Care Medicine. Title of the article was "Cardiovascular and Neuropsychiatric Events Following Varenicline Use for Smoking Cessation."
The Diabetes News Chronicle does not provide medical advice, diagnosis or treatment. Information in Diabetes News Chronicle is to support and not to replace medical advice given by the surgeon or physician or doctor. Published article is not a medical advice by the OWNER of "Diabetes News Chronicle" website or by the AUTHOR of the article.
Published by Jammi Vasista, Chennai, India.